Bordetella pertussis Jill Angelosanto Bio 360

Outline Bordetella Pertussis microbiology Bordetella Pertussis microbiology Whooping Cough/Pertussis Whooping Cough/Pertussis Vaccine Vaccine Current problems with B. pertussis Current problems with B. pertussis

Bordetella pertussis Basics Aerobic, Gram negative coccobacillus Aerobic, Gram negative coccobacillus Alcaligenaceae Family Alcaligenaceae Family Specific to Humans Specific to Humans Colonizes the respiratory tract Colonizes the respiratory tract Whooping Cough (Pertussis) Whooping Cough (Pertussis) gram_pertussis.html

Transmission Very Contagious Very Contagious Transmission occurs via respiratory droplets Transmission occurs via respiratory droplets

Virulence Steele, R.W. Pertussis: Is Eradication Achievable. Pediatric Annals. Aug (8):

Adhesions Filamentous hemagglutinin Filamentous hemagglutinin Pertactin Pertactin Fimbriae Fimbriae

Toxins Pertussis Toxin Pertussis Toxin Adenylate Cyclase Toxin Adenylate Cyclase Toxin Tracheal cytotoxin Tracheal cytotoxin Dermonecrotic toxin Dermonecrotic toxin Heat-labile toxin Heat-labile toxin

Pertussis Toxin Colonizing factor and endotoxin Colonizing factor and endotoxin Cell bound and extracellular Cell bound and extracellular gsbs.utmb.edu/ microbook/ch031.htm ghaffar/pertussis.jpg

Adenylate Cyclase Toxin Invasive toxin Invasive toxin Activated by host cell calmodulin Activated by host cell calmodulin Impairment of immune effector cells Impairment of immune effector cells Babu et al., 2001

The bvg locus Controls expression of virulence factors Controls expression of virulence factors Encodes BvgA, BvgS and BvgR Encodes BvgA, BvgS and BvgR BvgA-BvgS signal transduction system BvgA-BvgS signal transduction system Babu et al., 2001

Whooping Cough Also known as Pertussis Also known as Pertussis Outbreaks first described in the 16 th Century Outbreaks first described in the 16 th Century Major cause of childhood fatality prior to vaccination Major cause of childhood fatality prior to vaccination paaap.org/immunize/ course/slide27.html

Clinical Features Incubation period 4-21 days Incubation period 4-21 days 3 Stages 3 Stages 1 st Stage- Catarrhal Stage 1-2 weeks 1 st Stage- Catarrhal Stage 1-2 weeks 2 nd Stage- Paroxysmal Stage 1-6 weeks 2 nd Stage- Paroxysmal Stage 1-6 weeks 3 rd Stage- Covalescent Stage weeks-months 3 rd Stage- Covalescent Stage weeks-months

Pertussis Infection gsbs.utmb.edu/ microbook/ch031.htm

Diagnosis Isolation by culture Isolation by culture PCR PCR Direct fluorescent antibody Direct fluorescent antibody Serological testing Serological testing

Treatment Antibiotic therapy Antibiotic therapy Erythromycin Erythromycin Azithromycin and clarithromycin Azithromycin and clarithromycin FILENAME/ /033_lg.jpg

Pertussis Vaccine 1st Pertussis vaccine- whole cell 1st Pertussis vaccine- whole cell Acellular vaccine now used Acellular vaccine now used Combination vaccines Combination vaccines

Increase in Pertussis cases Incidence of disease increasing in countries with high vaccination levels Incidence of disease increasing in countries with high vaccination levels US- Massachusetts US- Massachusetts Netherlands Netherlands France France Finland Finland

Cases in

Massachusetts Yih et al., 2000 Substantial increase in the number of cases in adolescents and adults since 1980’s

Netherlands Mismatch between vaccine strains and circulating strains played role in reemergence Mismatch between vaccine strains and circulating strains played role in reemergence Mooi et al., 2001

Strain Variation B. pertussis population has changed significantly since vaccine introduction B. pertussis population has changed significantly since vaccine introduction Adaptation to vaccine Adaptation to vaccine Antigenic divergence Antigenic divergence Mooi et al., 2001

Vaccine problems Complications/Safety Complications/Safety Multiple administration Multiple administration Waning adolescent and adult immunity Waning adolescent and adult immunity Strain Variability Strain Variability

Conclusions Reemerging in adult and adolescent populations as worldwide vaccination rates increase Reemerging in adult and adolescent populations as worldwide vaccination rates increase High vaccination rates not enough High vaccination rates not enough Better vaccine development needed Better vaccine development needed

References Ahuja, N., Kumar, P., Bhatnagar, R. The Adenylate Cyclase Toxins. Critical Reviews in Microbiology. 2004; 30(3): Babu, MM., Bhargavi, J., Singh Saund, R., Singh, S.K. Virulence Factors in Bordetella pertussis. Current Science. June 2001; 80(12): Coote, JG. Environmental Sensing Mechanisms in Bordetella. Advances in Microbial Physiology. 2001; 44: Dalet, K., Weber, C., Guillemot, L., Njamkepo, E., Guiso, N. Characterization of Adenylate Cyclase- Hemolysin Gene Duplication in a Bordetella pertussis isolate. Infection and Immunity. Aug 2004; 72(8): Forsyth, K.D., Campins-Marti, M., Caro, J., Cherry, J.D., Greenberg, D., Guiso, N., Heininger, U., Schellenkens, J., Tan, T., von Konig, C., Plotkin, S. New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative. Clinical Infectious Diseases. Dec 2004: 39: Hardwick, T.H., Cassiday, P., Weyant, R.S., Bisgard, K.M., Sanden, G.N. Changes in the Predominance and Diversity of Genomic Subtypes of Bordetella pertussis Isolated in the United States, Emerging Infectious Diseases. Jan 2002; 8(1): Mattoo, S., Foreman-Wykert, A., Cotter, P., Miller, J. Mechanisms of Bordetella Pathogenesis. Frontiers in Bioscience. Nov 2001; 6: E Merkel, T.J., Stibitz, S., Keith, J.M., Leef, M., Shahin, R. Contribution of Regulation by the bvg Locus to Respiratory Infection of Mice by Bordetella pertussis. Infection and Immunity. Sept 1998; 66(9):

Reference cont. Mooi, F.R., van Loo, I.H.M., King, A.J. Adaptation of Bordetella pertussis to Vaccination: A Cause for Its Reemergence? Emerging Infectious Disease. June 2001; 7(No. 3 Supplement): Pishko, E.J., Betting, D.J., Hutter, C.S., Harvill, E.T. Bordetella pertussis Aquires Resistance to Complement Mediated Killing In Vivo. Infection and Immunity. Sept 2003; 71(9): Robbins, J.B., Schneerson, R., Trollfors, B., Sato, H., Sato, Y., Rappuoli, R., Keith., J.M. The Diphtheria and Pertussis Components of the Diphtheria-Tetanus Toxoids-Pertussis Vaccine Should Be Genetically Inactivated Mutant Toxins. The Journal of Infectious Diseases. 2005;191: Schouls, L.M., van der Heide, H.G.J., Vauterin, L., Vaurerin, P., Mooi, F.R. Multiple-Locus Variable- Number Tandem Repeat Analysis of Dutch Bordetella pertussis Strains Reveals Rapid Genetic Changes with Clonal Expansion during the Late 1990s. Journal of Bacteriology. Aug 2004; 186(16): Shumilla, J.A., Lacaille, V., Hornell, M.C., Haung, J., Narasimhan, S., Relman, D.A., Mellins, E.D. Bordetella Pertussis Infection of Primary Human Monocytes Alters HLA-DR Expression. Infection and Immunity. Mar 2004; 72(3): Steele, RW. Pertussis: Is Eradication Achievable? Pediatric Annals. Aug 2004; 33(8): Veal-Carr, W., Stibitz, S. Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET. Molecular Microbiology. 2005; 55(3): Yih, W.K., Lett, S.M., des Vignes, F.N., Garrison, K.M., Sipe, P.L., Marchant, C.D. The Increasing Incidence of Pertussis in Massachusetts Adolescents and Adults, The Journal of Infectious Diseases. 2000; 182: